Company / SG&A Expense
NovoCure Ltd SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$177.7M
FY2025
5-year range
$126.1M / $189.8M
FY2021-FY2025
Trend
-6.4%
vs FY2024
Sector context
#109 of 152
Health Care
What the data says
At $178M, NovoCure Ltd's sg&a expense ranks #44 of 152 in the Health Care sector. Increased from $164M to $178M over the past 2 years.
Based on SEC 10-K filings.
$178M in FY2025 with a 5-year CAGR of +10.6%.
Increased from $164M to $178M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +10.2%
- 5-Year CAGR
- +10.6%
- 10-Year CAGR
- -
Sector benchmark
#44 of 152 in Health CareTop 28% of 152This company $177.7M Sector average $182.7B
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +10.6%, indicating consistent growth.
- In FY2025, sg&a expense decreased 6.4% year-over-year.
- Ranks #109 out of 152 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $177.7M | -6.4% |
| FY2024 | $189.8M | +15.7% |
| FY2023 | $164.1M | +23.6% |
| FY2022 | $132.8M | +5.3% |
| FY2021 | $126.1M | +17.4% |
| FY2020 | $107.4M | +22.2% |
| FY2019 | $87.9M | +19.7% |
| FY2018 | $73.5M | +24.3% |
| FY2017 | $59.1M | +15.9% |
| FY2016 | $51.0M | +50.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026